Paragraph (b) of Item 2 of the Schedule 13D shall hereby be amended and restated in full as follows: The business address of Mr. Lynch, Mr. Petito and Mr. Yanagi, and the address of the principal business and the principal office of the Fund and the GP, is 334 Pemberwick Road, Second Floor, Greenwich, CT 06831.

Paragraph (c) of Item 2 of the Schedule 13D shall hereby be amended and restated in full as follows: The principal business of the GP is acting as the sole general partner of the Fund. The principal business of the Fund is investing in securities. The present principal occupation or employment of each Manager is as a Management Committee Director of the GP and Mill Road Capital Management LLC, a Delaware limited liability company (the "Management Company"), which provides advisory and administrative services to the GP and the Fund. Mr. Lynch also serve as Chairman of the GP and the Management Company. The principal office of the Management Company is located at 334 Pemberwick Road, Second Floor, Greenwich, CT 06831.

Item 3 of the Schedule 13D shall hereby be amended and restated in its entirety as follows: The Reporting Persons have acquired beneficial ownership of an aggregate of 1,063,079 shares of Common Stock for $15,869,235 using working capital from the Fund and the proceeds of margin loans under margin loan facilities maintained in the ordinary course of business by the Fund with a broker on customary terms and conditions.

Paragraph (a) of Item 5 of the Schedule 13D shall hereby be amended and restated in full as follows: The percentages of beneficial ownership reported in this Item 5, and on each Reporting Person's cover page to this Schedule 13D, are based on a total of 22,855,008 shares of Common Stock issued and outstanding as of April 30, 2026, as reported in the Issuer's quarterly report on Form 10-Q for the fiscal quarter ended March 31, 2026. All of the share numbers reported herein are as of June 17, 2026, unless otherwise indicated. Each Reporting Person's cover page to this Schedule 13D is incorporated by reference into this Item 5(a) and Item 5(b). Each of the Reporting Persons beneficially owns 1,063,079 shares of Common Stock, or approximately 4.7% of the outstanding shares of Common Stock, and the Reporting Persons beneficially own, in the aggregate, 1,063,079 shares of Common Stock, or approximately 4.7% of the outstanding shares of Common Stock.

Paragraph (b) of Item 5 of the Schedule 13D shall hereby be amended and restated in full as follows: The Fund directly holds, and thus has sole voting and dispositive power over, 1,063,079 shares of Common Stock. The GP, as sole general partner of the Fund, also has sole authority to vote (or direct the vote of), and to dispose (or direct the disposal) of, these shares on behalf of the Fund, and Mr. Lynch has shared authority to vote (or direct the vote of), and to dispose (or direct the disposal) of, these shares in his capacity as Chairman and Management Committee Director of the GP.

Paragraph (c) of Item 5 of the Schedule 13D shall hereby be amended and restated in full as follows: Except as otherwise described in this Schedule 13D, no Reporting Person, other than the Fund as set forth in the table below, effected any transaction in the Common Stock from April 18, 2026 (the date 60 days prior to the filing of this Schedule 13D) to June 17, 2026 (the "Reporting Period"): Date of Sale Shares Sold (#) Sale Price per Share ($) 6/15/2026 1,382 $9.2930 6/16/2026 1,349 $9.2424 Except as otherwise described in this Schedule 13D, the above-listed transactions were conducted in the ordinary course of business on the open market for cash, and the sale prices do not reflect brokerage commissions paid. In addition, during the Reporting Period, the Fund sold the Call Options described in Item 6, which is incorporated by reference into this Item 5(c).

January 29, 2024

Item 6 of the Schedule 13D shall hereby be amended and restated in full as follows: The table below lists the standard American-style, exchange-traded call options ("Call Options") sold by the Fund during the Reporting Period. The below listed transactions were conducted in the ordinary course of business on the open market for cash, and the sale prices does not reflect brokerage commissions paid. Date of Sale Value per Underlying Shares Underlying Call Options' Strike Call Options' Share at which Call Call Options (100s) Price per Share ($) Expiration Date Options were Sold ($) 6/16/2026 $2.2899 798 $7.50 11/20/2026 6/17/2026 $2.2653 410 $7.50 11/20/2026 Each of these Call Options gives the option's counterparty the right (but not the obligation) to purchase from the Fund, on or before the option's expiration date, the number of shares of Common Stock underlying the option, at a purchase price per share equal to the option's strike price per share. If a Call Option is exercised on or before its expiration date, the Fund must deliver the shares of Common Stock underlying the option in exchange for the option's aggregate exercise price. Except as otherwise described in this Schedule 13D, including the Exhibits attached hereto, there are no contracts, arrangements, understandings or relationships (legal or otherwise) among the Reporting Persons, or between the Reporting Persons and any third party, with respect to any securities of the Issuer, including, but not limited to, those involving the transfer or voting of securities, finder's fees, joint ventures, loan or option arrangements, puts or calls, guarantees of profits, division of profits or losses, or the giving or withholding of proxies.